Right of Reference and License Agreement - Additional Information (Details) - GSK Agreement - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2022
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones		$ 5.0
Specified clinical and regulatory milestones phase two clinical trial		2.5
Research and Development
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	$ 5.0
Maximum
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones		37.5
Specified sales milestone		$ 60.0
Series B Convertible Preferred Stock
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Shares issued for asset acquisition		12,500,000